NCI and all five cooperative groups that make up the National Clinical Trials Network have launched a large-scale precision medicine initiative that will match cancer patients with early-phase clinical trials testing novel drug combinations that target specific tumor alterations.
How’s this for a paradox: The better cancer centers become at keeping patients alive, the more expensive cancer care becomes. This brutal tradeoff hits harder in rural areas, where the cancer burden is higher and the investigator and clinical trial representation is lower.
